Free Trial

What is KeyCorp's Forecast for CryoPort FY2025 Earnings?

CryoPort logo with Transportation background

Key Points

  • KeyCorp has issued a forecast for CryoPort's FY2025 earnings, expecting a loss of ($0.85) per share, improved from a consensus estimate of ($0.99).
  • CryoPort reported a revenue of $45.45 million for the latest quarter, exceeding expectations, but posted a quarterly EPS loss of ($0.29), missing the consensus of ($0.20).
  • Several analysts have upgraded their ratings on CryoPort, with one firm setting a price target as high as $16.00, reflecting positive sentiment among experts despite current losses.
  • Need Better Tools to Track CryoPort? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

CryoPort, Inc. (NASDAQ:CYRX - Free Report) - Stock analysts at KeyCorp issued their FY2025 earnings per share estimates for shares of CryoPort in a research note issued to investors on Tuesday, August 5th. KeyCorp analyst P. Knight expects that the company will post earnings per share of ($0.85) for the year. KeyCorp currently has a "Overweight" rating and a $15.00 target price on the stock. The consensus estimate for CryoPort's current full-year earnings is ($0.99) per share.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The company had revenue of $45.45 million for the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a negative return on equity of 10.48% and a net margin of 37.21%.

Other equities research analysts have also issued research reports about the stock. Leerink Partnrs upgraded shares of CryoPort from a "hold" rating to a "strong-buy" rating in a research note on Wednesday. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price target for the company in a report on Wednesday. Stephens assumed coverage on CryoPort in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of CryoPort in a report on Thursday, May 8th. Finally, BTIG Research reduced their target price on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, July 7th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $12.00.

Check Out Our Latest Analysis on CYRX

CryoPort Trading Up 0.8%

NASDAQ CYRX opened at $8.27 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 5.24 and a current ratio of 5.56. The company has a 50-day simple moving average of $7.17 and a 200-day simple moving average of $6.60. CryoPort has a one year low of $4.58 and a one year high of $9.66. The firm has a market capitalization of $414.41 million, a PE ratio of 6.21 and a beta of 1.88.

Insider Activity

In related news, Director Ramkumar Mandalam sold 40,728 shares of the company's stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total value of $294,870.72. Following the completion of the transaction, the director directly owned 92,328 shares in the company, valued at approximately $668,454.72. The trade was a 30.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Edward J. Zecchini sold 51,500 shares of the firm's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $6.84, for a total value of $352,260.00. Following the transaction, the insider directly owned 90,411 shares in the company, valued at $618,411.24. This trade represents a 36.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 490,447 shares of company stock valued at $3,337,198 in the last quarter. 10.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CryoPort

Several institutional investors have recently made changes to their positions in CYRX. Rhumbline Advisers increased its position in CryoPort by 23.8% in the first quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock worth $476,000 after purchasing an additional 15,036 shares during the last quarter. Graham Capital Management L.P. grew its position in shares of CryoPort by 24.9% during the 4th quarter. Graham Capital Management L.P. now owns 28,460 shares of the company's stock worth $221,000 after buying an additional 5,667 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of CryoPort in the fourth quarter valued at about $51,000. ProShare Advisors LLC purchased a new stake in CryoPort in the fourth quarter worth about $95,000. Finally, CWM LLC grew its holdings in CryoPort by 1,437.0% during the 1st quarter. CWM LLC now owns 11,328 shares of the company's stock worth $69,000 after acquiring an additional 10,591 shares in the last quarter. Institutional investors own 92.90% of the company's stock.

About CryoPort

(Get Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

Featured Articles

Earnings History and Estimates for CryoPort (NASDAQ:CYRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CryoPort Right Now?

Before you consider CryoPort, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.

While CryoPort currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines